title: "Orostim"--polymicrobial preparation for oral administration. I. "In vivo" determination of toxicity and of inborn resistance stimulation characteristic.
abstract: "Orostim" is a polymicrobial immunomodulator for oral administration, obtained from bacterial suspensions, disintegrated by ultrasonics and dried by atomization. The preparation was chemically characterized before and after atomization without presenting essential modifications. Orostim was not shown to be toxic in mice and rats by esophageal intubation, as long as 20 days. The animals presented normal evolution; hemoleukograms, serum proteins and alkaline phosphatase, in rats, did not present significant modifications in comparison with controls. Histopathologic examination of the organs, obtained from mice, treated for 20 days (liver, spleen, lung) did not emphasize modifications in comparison with controls. Circulating neutrophils phagocytosis in rabbits, orally treated with Orostim, was increased as compared to 0 time; serum complement values decreased compared to the initial ones for 0 time but turned to normal and reached even superior limits, 10 days after the treatment ending.
authors.forename: S
authors.initials: S
authors.lastname: Hoişie
authors.forename: I
authors.initials: I
authors.lastname: Pencea
authors.forename: G
authors.initials: G
authors.lastname: Dimache
authors.forename: E C
authors.initials: EC
authors.lastname: Lupuşoru
authors.forename: E
authors.initials: E
authors.lastname: Grigoraş
authors.forename: V
authors.initials: V
authors.lastname: Oiţă
authors.forename: R
authors.initials: R
authors.lastname: Buzdzgan
authors.forename: D A
authors.initials: DA
authors.lastname: Anton
authors.forename: O N
authors.initials: ON
authors.lastname: Ionescu
authors.forename: S
authors.initials: S
authors.lastname: Uliciuc
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*; D000284:Administration, Oral; D000818:Animals; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*; D001685:Biological Factors / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*; D004353:Drug Evaluation, Preclinical; D005260:Female; D007113:Immunity, Innate / Q000187:drug effects / Q000276:immunology; D007710:Klebsiella Infections / Q000473:pathology / Q000517:prevention & control; D007711:Klebsiella pneumoniae; D008297:Male; D051379:Mice; D010587:Phagocytosis / Q000187:drug effects / Q000276:immunology; D011817:Rabbits; D012481:Salmonella Infections, Animal / Q000473:pathology / Q000517:prevention & control; D012486:Salmonella typhimurium; D013203:Staphylococcal Infections / Q000473:pathology / Q000517:prevention & control; D013849:Thimerosal / Q000008:administration & dosage / Q000737:chemistry / Q000633:toxicity*
chemical_list: D000276:Adjuvants, Immunologic; D001428:Bacterial Vaccines; D001685:Biological Factors; D013849:Thimerosal